Ester Marina-Zárate

1 month ago | jci.org | Parham Ramezani-Rad |Ester Marina-Zárate |Laura Maiorino |Amber Myers

ResearchAIDS/HIVImmunologyOpen Access | 10.1172/JCI185292 J Clin Invest. https://doi.org/10.1172/JCI185292. Copyright © 2025, Ramezani-Rad et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Nov 22, 2024 | biorxiv.org | Patrick Madden |Ester Marina-Zárate |Kristen A. Rodrigues |Jon M. Steichen

AbstractRare B cells can have special pathogen-recognition features giving them the potential to make outsized contributions to protective immunity. However, rare naive B cells infrequently participate in immune responses. We investigated how germline-targeting vaccine antigen delivery and adjuvant selection affect priming of exceptionally rare BG18-like HIV broadly neutralizing antibody-precursor B cells (~1 in 50 million) in non-human primates.

Aug 3, 2024 | biorxiv.org | Parham Ramezani-Rad |Ester Marina-Zárate |Laura Maiorino |Amber Myers

AbstractThe induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play an important role as drivers of such responses. Despite advances in vaccine strategies, a safe and effective HIV vaccine remains a significant challenge. The use of an appropriate adjuvant is crucial to the success of HIV vaccines.

Jun 14, 2024 | nature.com | Ivy Phung |Olivia K. Swanson |Chang-Chun D. Lee |Ester Marina-Zárate |Gabriel Ozorowski |Kimmo Rantalainen | +28 more

Correction to: Nature Immunology https://doi.org/10.1038/s41590-024-01833-w, published online 30 May 2024In the version of the article initially published, Steven Schultze’s surname appeared incorrectly (as Schulze) and has now been amended in the HTML and PDF versions of the article.

May 30, 2024 | nature.com | Ivy Phung |Olivia K. Swanson |Chang-Chun D. Lee |Ester Marina-Zárate |Gabriel Ozorowski |Kimmo Rantalainen | +28 more

AbstractA key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of priming immunogens that induce rare bnAb-precursor B cells.